Radius Health - RDUS Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last twelve months. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RDUS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View RDUS analyst ratings or view top-rated stocks.

5 equities research analysts have issued twelve-month price objectives for Radius Health's shares. Their RDUS share price forecasts range from $7.00 to $10.00. On average, they anticipate the company's share price to reach $8.60 in the next twelve months. This suggests that the stock has a possible downside of 14.7%.
View analysts price targets for RDUS or view top-rated stocks among Wall Street analysts.

Radius Health's stock was trading at $6.92 at the beginning of the year. Since then, RDUS stock has increased by 45.7% and is now trading at $10.08.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RDUS earnings forecast.

Radius Health, Inc. (NASDAQ:RDUS) released its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of $0.08 by $0.35. The biopharmaceutical company earned $58.29 million during the quarter, compared to analyst estimates of $67.95 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Shares of RDUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RDUS stock can currently be purchased for approximately $10.08.

Radius Health (NASDAQ:RDUS) has a market capitalization of $480.01 million and generates $229.97 million in revenue each year. The biopharmaceutical company earns $-70,180,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

The company employs 293 workers across the globe.

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.radiuspharm.com. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at bryan@radiuspharm.com, or via fax at 617-551-4701.